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or malignancy) associated with filter placement, whereas
less than one third presented with thromboembolic disease
as the reason for treatment. IVC filters were placed in a
large number of patients in the current study for prophy-
laxis or contraindications to anticoagulation. This clinical
profile is quite different from that of patients presenting
with primary DVT, who are often outpatients without
another intercurrent illness or underlying malignancy. It is
easy to imagine that the latter group would have a higher
incidence of hypercoagulable conditions. This factor alone
might lead to differences in the observed rate of late events
when the current report is compared with reports from the
literature. The unique characteristics of the current report
preclude any conclusions on the effect of anticoagulation
on the late incidence of recurrent DVT.
As the authors state in their report, placing an IVC fil-
ter cannot be expected to influence the course of DVT,
which must be treated “based on an individual risk/bene-
fit assessment.” Good clinical practice dictates that the eti-
ology of DVT in each instance be determined and
appropriately addressed. In patients with self-limited prob-
lems such as surgery or trauma, which preclude early anti-
coagulant therapy, anticoagulation may and often should
be instituted during follow-up when the risk of hemor-
rhage has decreased. In those cases the duration of antico-
agulation is not established, but may, in fact, be
abbreviated. However, when patients present with more
chronic conditions such as malignancy or hypercoagulable
states, treatment with anticoagulants will need to be more
prolonged and may be indefinite.
The authors make several important observations.
IVC filters can be placed safely with good long-term
patency and no apparent increase in the incidence of DVT.
They also observe that although anticoagulation may be
initially deferred, it can be initiated later in the patient’s
course, a fact that is often overlooked. One must not con-
clude from these data, however, that the issue of long-
term treatment of DVT with anticoagulation is of little
consequence. The authors have not performed a study
designed to test this hypothesis. In clinical practice this is
often the conclusion drawn. It is more important, I
believe, to treat the whole patient rather than the disease
and to be as vigilant in the appropriate treatment of DVT
as one is in the prevention of pulmonary embolism.
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Please see related article by Greenfield and Proctor on
pages 510-4.
In this issue of the Journal of Vascular Surgery,
Greenfield and Proctor present their analysis of a large
prospectively collected database that includes consecutive
patients treated with Greenfield vena cava filters. As the
authors note, there are significant limitations to their data
set: inconsistencies in the determination of hard end
points, incomplete follow-up, and poor quantitative data
on the degree and duration of anticoagulation. Although
these limitations do constrain the conclusions that can be
drawn from the data, their article provides a unique
insight into the late results of filter placement in a large
number of patients with extended follow-up.
The data show that inferior vena cava (IVC) filters can
be placed with a low incidence of technical complications
(< 4%) and minimal late morbidity. Their follow-up docu-
ments a high (> 99%) incidence of caval patency, and they
can show no detrimental effect of IVC filter placement on
the incidence of late deep venous thrombosis (DVT).
These observations, particularly if they can be generalized,
are reassuring at a time when the practice of prophylactic
filter placement is increasing. I believe that these conclu-
sions drawn by the authors can be substantiated by their
data. The authors go on to suggest that anticoagulation
plays a minor role in the incidence of late DVT. This asser-
tion is contrary to the “accepted wisdom” concerning the
management of DVT and, if accepted, would have signif-
icant clinical implications. As such it needs to be carefully
scrutinized. After scrutiny, I do not believe that this con-
clusion can be drawn on the basis of the data presented.
To do so, the authors would need data on the duration
and adequacy of anticoagulation, the incidence of symp-
tomatic and asymptomatic DVT, and the underlying cause
of the thromboembolic events that occurred. These data
are not presented in this article.
Despite the fact that the authors focused on patients
with “thromboembolic disease” at the time of filter place-
ment, their population is in many ways unique and distinct
from that of patients with primary DVT. In the current
study, all patients had an IVC filter placed and therefore, by
definition, were inpatients. More than 50% of these
patients had an acute intercurrent event (trauma, surgery,
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